Duration of effect of oral long-acting stimulant medications for ADHD throughout the day

References

• Strine TW, Lesesne CA, Okoro CA, et al. Emotional and behavioral difficulties and impairments in everyday functioning among children with a history of attention-deficit/hyperactivity disorder. Prev Chronic Dis 2006;3:A52
   PubMedGoogle Scholar
• Sawyer MG, Whaites L, Rey JM, et al. Health-related quality of life of children and adolescents with mental disorders. J Am Acad Child Adolesc Psychiatry 2002;41:530-7
   PubMed Web of Science ®Google Scholar
• Katragadda S, Schubiner H. ADHD in children, adolescents, and adults. Prim Care 2007;34:317-41
   PubMed Web of Science ®Google Scholar
• Goodman DW. The consequences of attention-deficit/hyperactivity disorder in adults. J Psychiatr Pract 2007;13:318-27
   PubMedGoogle Scholar
• Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 2006;67:524-40
   PubMed Web of Science ®Google Scholar
• Biederman J, Petty C, Fried R, et al. Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 2006;163:1730-8
   PubMed Web of Science ®Google Scholar
• Barkley RA, Fischer M, Smallish L, et al. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 2006;45:192-202
   PubMed Web of Science ®Google Scholar
• Barkley RA. Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:233-60
   PubMed Web of Science ®Google Scholar
• Barkley RA, Guevremont DC, Anastopoulos AD, et al. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. Pediatrics 1993;92:212-8
   PubMed Web of Science ®Google Scholar
• Froehlich TE, Lanphear BP, Epstein JN, et al. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med 2007;161:857-64
   PubMed Web of Science ®Google Scholar
• Pastor PN, Reuben CA. Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006. National Center for Health Statistics. Vital Health Stat 2008;10:1-14
   Google Scholar
• Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-8
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23
   PubMed Web of Science ®Google Scholar
• Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001;40:147-58
   PubMed Web of Science ®Google Scholar
• Pliszka S, and the AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921
   PubMed Web of Science ®Google Scholar
• Canadian ADHD Resource Alliance. Canadian ADHD Practice Guidelines. CADDRA 2008. http://www.caddra.ca/cms4/index.php?option=com_content&view=article&id=26&Itemid=353&lang=en. Accessed December 14, 2009
   Google Scholar
• Faraone SV. Interpreting estimates of treatment effects. Implications for managed care. P T 2008;33:700-1
   Google Scholar
• Ritalin LA [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2009
   Google Scholar
• Carlson GA, Kelly KL. Stimulant rebound: how common is it and what does it mean?. J Child Adolesc Psychopharmacol 2003;13:137-42
   PubMed Web of Science ®Google Scholar
• Cox DJ, Moore M, Burket R, et al. Rebound effects with long-acting amphetamine or methylphenidate stimulant medication preparations among adolescent male drivers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008;18:1-10
   PubMed Web of Science ®Google Scholar
• Ramos-Quiroga JA, Bosch R, Castells X, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 2008;22:603-11
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Zhang HF, et al. Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. J Manag Care Pharm 2007;13:570-7
   PubMed Web of Science ®Google Scholar
• Castle L, Aubert RE, Verbrugge RR, et al. Trends in medication treatment for ADHD. J Atten Disord 2007;10:335-42
   PubMedGoogle Scholar
• Connor DF, Steingard RJ. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential. CNS Drugs 2004;18:1011-30
   PubMed Web of Science ®Google Scholar
• Abikoff H, Hechtman L. Multimodal therapy and stimulants in the treatment of children with attention deficit hyperactivity disorder. In: Hibbs ED, Jensen PS, eds. Psychosocial Treatments for Child and Adolescent Disorders: Empirically Based Strategies for Clinical Practice. Washington, DC: APA Press, 1996: 341-69
   Google Scholar
• Pelham WE Jr, Fabiano GA. Behavior modification. Child Adolesc Psychiatr Clin North Am 2000;9:671-88, ix
   PubMed Web of Science ®Google Scholar
• Weiss M, Bailey R. Advances in the treatment of adult ADHD—landmark findings in nonstimulant therapy. http://www.medscape.com/viewarticle/458059_1. Accessed April 13, 2009
   Google Scholar
• Weiss MD, Weiss JR. A guide to the treatment of adults with ADHD. J Clin Psychiatry 2004;65(Suppl 3):27-37
   PubMed Web of Science ®Google Scholar
• Wolraich ML, McGuinn L, Doffing M. Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations. Drug Saf 2007;30:17-26
   PubMed Web of Science ®Google Scholar
• Adler LA, Goodman D, Weisler R, et al. Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder. Behav Brain Funct 2009;5:34
   PubMed Web of Science ®Google Scholar
• Conners CK, Sitarenios G, Parker JDA, et al. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998;26:257-68
   PubMed Web of Science ®Google Scholar
• Weisler RH, Biederman J, Spencer TJ, et al., on behalf of the SLI381.303 Study Group. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006;11:625-39
   PubMed Web of Science ®Google Scholar
• Pelham WE, Gnagy EM, Chronis AM, et al. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 1999;104:1300-11
   PubMed Web of Science ®Google Scholar
• Pelham WE, Aronoff HR, Midlam JK, et al. A comparison of Ritalin® and Adderall®: efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pediatrics 1999;103:e43
   PubMed Web of Science ®Google Scholar
• Wigal SB, Swanson JM, Greenhill L, et al. Evaluation of individual subjects in the analog classroom setting: II. Effects of dose of amphetamine (Adderall®). Psychopharmacol Bull 1998;34:833-8
   PubMed Web of Science ®Google Scholar
• Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta® methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001;107:E105
   Google Scholar
• Wigal SB, Wigal TL. The laboratory school protocol: its origin, use, and new applications. J Atten Disord 2006;10:92-111
   PubMedGoogle Scholar
• Brams M. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using the adult workplace environment design. Behav Brain Func. Accepted for publication, 2010
   Google Scholar
• Wigal SB, Gupta S, Guinta D, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 1998;34:47-53
   PubMed Web of Science ®Google Scholar
• Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007;62:970-6
   PubMed Web of Science ®Google Scholar
• Wigal SB, Kollins SH, Childress AC, et al., for the 311 Study Group. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 2009;3:17
   PubMedGoogle Scholar
• Swanson JM, Wigal SB, Wigal T, et al. and the COMACS Study Group. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The Comacs Study). Pediatrics 2004;113:e206-16
   PubMed Web of Science ®Google Scholar
• Swanson J, Wigal S, Greenhill L, et al. Objective and subjective measures of the pharmacodynamic effects of Adderall® in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 1998;34:55-60
   PubMed Web of Science ®Google Scholar
• Lopez F, Silva R, Pestreich L, et al. Comparative efficacy of two once daily methylphenidate formulations (Ritalin® LA and Concerta®) and placebo in children with attention deficit hyperactivity disorder across the school day. Pediatr Drugs 2003;5:545-55
   PubMedGoogle Scholar
• Silva R, Muniz R, Pestreich LK, et al. Efficacy of two long-acting methylphenidate formulations in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting. J Child Adolesc Psychopharmacol 2005;15:637-54
   PubMed Web of Science ®Google Scholar
• Quinn D, Wigal S, Swanson J, et al. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004;43:1422-9
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Swanson JM, Steinhoff K, et al. A pharmacokinetic/pharmacodynamic study comparing a single morning dose of Adderall to twice-daily dosing in children with ADHD. J Am Acad Child Adolesc Psychiatry 2003;42:1234-41
   PubMed Web of Science ®Google Scholar
• Swanson JM, Gupta S, Williams L, et al. Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry 2002;41:1306-14
   PubMed Web of Science ®Google Scholar
• Swanson J, Gupta S, Guinta D, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 1999;66:295-305
   PubMed Web of Science ®Google Scholar
• Swanson JM, Wigal S, Greenhill LL, et al. Analog classroom assessment of Adderall® in children with ADHD. J Am Acad Child Adolesc Psychiatry 1998;37:519-26
   PubMed Web of Science ®Google Scholar
• Wigal SB, Sanchez DY, DeCory HH, et al. Selection of the optimal dose ratio for a controlled-delivery formulation of methylphenidate. J Appl Res 2003;3:46-63
   Google Scholar
• Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR®) and atomoxetine (Strattera®) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005;9:275-89
   PubMedGoogle Scholar
• Findling RL, Bukstein OG, Melmed RD, et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clinl Psychiatry 2008;69:149-59
   PubMed Web of Science ®Google Scholar
• Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007;29:450-63
   PubMed Web of Science ®Google Scholar
• Sonuga-Barke EJS, Swanson JM, Coghill D, et al. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 2004;4:28
   PubMed Web of Science ®Google Scholar
• Sonuga-Barke EJS, Coghill D, Markowitz JS, et al. Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate. J Am Acad Child Adolesc Psychiatry 2007;46:701-10
   PubMed Web of Science ®Google Scholar
• Sonuga-Barke EJS, Van Lier P, Swanson JM, et al. Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder: a growth mixture modelling analysis. Eur Child Adolesc Psychiatry 2008;17:245-54
   PubMed Web of Science ®Google Scholar
• McCracken JT, Biederman J, Greenhill LL, et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry 2003;42:673-83
   PubMed Web of Science ®Google Scholar
• James RS, Sharp WS, Bastain TM, et al. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry 2001;40:1268-76
   PubMed Web of Science ®Google Scholar
• Faraone SV. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder. Expert Opin Pharmacother 2008;9:1565-74
   PubMed Web of Science ®Google Scholar
• Ermer J, Homolka R, Martin P, et al. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers [published online ahead of print February 19, 2010]. J Clin Pharmacol doi:10.1177/009127000935736
   Google Scholar
• Tulloch SJ, Zhang Y, McLean A, et al. SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy 2002;22:1405-15
   PubMed Web of Science ®Google Scholar
• Adderall [package insert]. Pamona, NY: Barr Pharmaceuticals Inc., 2007
   Google Scholar
• McGough JJ, Biederman J, Greenhill LL, et al. Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. J Am Acad Child Adolesc Psychiatry 2003;42:684-91
   PubMed Web of Science ®Google Scholar
• Adderall XR [package insert]. Wayne, PA: Shire US Inc., 2009
   Google Scholar
• Dexedrine Spansule [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2009
   Google Scholar
• Faraone SV, Pucci M, Coghill D. Pharmacotherapy for attention-deficit-hyperactivity disorder. US Psychiatry Rev 2009;2:17-27
   Google Scholar
• Ritalin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2009
   Google Scholar
• Döpfner M, Gerber WD, Banaschewski T, et al. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry 2004;13(Suppl 1):I93-101
   PubMedGoogle Scholar
• Silva RR, Muniz R, Pestreich L, et al. Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006;16:239-51
   PubMed Web of Science ®Google Scholar
• Muniz R, Brams M, Mao A, et al. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol 2008;18:248-56
   PubMed Web of Science ®Google Scholar
• Silva R, Muniz R, McCague K, et al. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and d,l-methylphenidate and placebo in a laboratory classroom setting. Psychopharmacol Bull 2008;41:19-33
   PubMed Web of Science ®Google Scholar
• Silva RR, Muniz R, Pestreich L, et al. Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2008;47:199-208
   PubMed Web of Science ®Google Scholar
• Brams M, Muniz R, Childress A, et al. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect. CNS Drugs 2008;22:693-704
   PubMed Web of Science ®Google Scholar
• Concerta (methylphenidate HCI) [package insert]. Titusville, NJ: McNeil Pediatrics, 2009
   Google Scholar
• Gonzalez MA, Pentikis HS, Anderl N, et al. Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 2002;40:175-84
   PubMed Web of Science ®Google Scholar
• Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003;60:204-11
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 2003;23:1281-99
   PubMed Web of Science ®Google Scholar
• McGough JJ, Pataki CS, Suddath R. Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder. Expert Rev Neurother 2005;5:437-41
   PubMedGoogle Scholar
• Tuerck D, Wang Y, Maboudian M, et al. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. Int J Clin Pharmacol Ther 2007;45:662-8
   PubMed Web of Science ®Google Scholar
• Wigal SB, Kollins S, Childress A, et al. Sustained efficacy of lisdexamfetamine dimesylate over 13 hours as assessed by effect size in children with attention-deficit/hyperactivity disorder. Poster presented at: the American Psychiatric Association's 162nd Annual Meeting; May 16-21, 2009, San Francisco, CA
   Google Scholar
• Kollins SH. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD). Am J Addict 2007;16(Suppl 1):35-44
   PubMed Web of Science ®Google Scholar
• Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med 2008;10:111
   PubMedGoogle Scholar
• Parasrampuria DA, Schoedel KA, Schuller R, et al. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. J Clin Pharmacol 2007;47:1476-88
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol 2009;23:410-18
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009;23:419-27
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006;163:387-95
   PubMed Web of Science ®Google Scholar
• Vyvanse [package insert]. Wayne, PA: Shire US Inc., 2009
   Google Scholar
• Metadate CD [package insert]. Smyrna, GA: UCB, Inc., 2008
   Google Scholar
• Focalin XR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2009
   Google Scholar
• Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009;48:484-500
   PubMed Web of Science ®Google Scholar
• Biederman J, Monuteaux MC, Spencer T, et al. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics 2009;124:71-8
   PubMed Web of Science ®Google Scholar